Search
Now showing items 1-10 of 17
HIV vaccines and immunity.
(Allergy Society of South Africa., 2003)
No abstract available.
Topical microbicides - What's new?
(Lippincott Williams & Wilkins., 2013)
Topical microbicides are an important, promising but complex HIV prevention technology under development. After 11 disappointing effectiveness trial outcomes of 6 candidate products (some tested as multiple doses and ...
Using mobile technology (pMOTAR) to assess reactogenicity: protocol for a pilot randomized controlled trial.
(JMIR Publications., 2018)
Abstract available in pdf.
Preservation HIV-1–specific IFNg+ CD4+ T-Cell responses in breakthrough infections after exposure to tenofovir gel in the CAPRISA 004 microbicide trial.
(Lippincott Williams & Wilkins., 2011)
Abstract: The Centre for the AIDS Program of Research in South Africa 004 trial demonstrated reduction of sexual HIV-1 acquisition in women using a vaginal microbicide containing tenofovir. A better understanding of the ...
Adherence challenges with drugs for pre-exposure prophylaxis to prevent HIV infection.
(Springer Verlag., 2013)
Background: There are 34 million people living with human immunodeficiency virus (HIV) worldwide and each year this number increases. Until a vaccine is discovered, the prevention of new HIV infections remains an urgent ...
Comparison of viral env proteins from acute and chronic infections with subtype C human immunodeficiency virus type 1 identifies differences in glycosylation and CCR5 utilization and suggests a new strategy for immunogen design.
(American Society for Microbiology., 2013)
Understanding human immunodeficiency virus type 1 (HIV-1) transmission is central to developing effective prevention strategies, including a vaccine.We compared phenotypic and genetic variation in HIV-1 env genes from ...
Phase I safety and immunogenicity evaluations of an alphavirus replicon HIV-1 subtype C gag vaccine in healthy HIV-1-uninfected adults.
(American Society for Microbiology., 2012)
On the basis of positive preclinical data, we evaluated the safety and immunogenicity of an alphavirus replicon HIV-1 subtype C gag vaccine (AVX101), expressing a nonmyristoylated form of Gag, in two double-blind, randomized, ...
Recommendations for the design and use of standard virus panels to assess neutralizing antibody responses elicited by candidate Human Immunodeficiency Virus Type 1 vaccines.
(American Society for Microbiology., 2005)
No abstract available.
Characterization of anti-HIV-1 neutralizing and binding antibodies in chronic HIV-1 subtype C infection.
(Elsevier., 2012)
Neutralizing (nAbs) and high affinity binding antibodies may be critical for an efficacious HIV-1 vaccine. We characterized virus-specific nAbs and binding antibody responses over 21 months in eight HIV-1 subtype C chronically ...
The development of CD4 binding site antibodies during HIV-1 infection.
(American Society for Microbiology., 2012)
Broadly neutralizing antibodies to the CD4 binding site (CD4bs) of gp120 are generated by some HIV-1-infected individuals, but little is known about the prevalence and evolution of this antibody response during the course ...